https://cdaf.org/conf-proceeding/the-impact-of-expanding-antiviral-treatment-criteria-at-a-population-level-in-the-republic-of-korea-a-modeling-analysis/2026-04-24T13:33:46-06:00https://cdaf.org/conf-proceeding/simplified-test-treat-protocols-to-eliminate-hcv-hbv-in-uzbekistan/2026-04-28T03:28:52-06:00https://cdaf.org/conf-proceeding/the-global-non-alcoholic-fatty-liver-disease-nafld-preparedness-index-are-countries-ready-to-tackle-the-challenge/2024-11-13T00:03:32-07:00https://cdaf.org/conf-proceeding/global-hbv-cascade-of-care-the-pre-covid-19-baseline/2024-11-13T00:03:22-07:00https://cdaf.org/conf-proceeding/cost-effectiveness-analysis-of-treating-all-hbsag-individuals-in-the-united-states/2024-11-13T00:03:17-07:00https://cdaf.org/conf-proceeding/modeling-hcv-elimination-recovery-following-the-covid-19-pandemic-in-the-united-states-pathways-to-regain-progress/2024-11-13T00:03:03-07:00https://cdaf.org/conf-proceeding/simplified-test-and-treat-protocols-for-population-level-screening-and-elimination-of-hepatitis-b-and-hepatitis-c-in-uzbekistan/2024-11-13T00:02:58-07:00https://cdaf.org/conf-proceeding/modeling-disease-burden-of-nonalcoholic-fatty-liver-disease-nafld-in-japan/2024-11-13T00:02:52-07:00https://cdaf.org/conf-proceeding/nafld-disease-burden-canada-2019-2030/2024-11-13T00:05:58-07:00https://cdaf.org/conf-proceeding/global-prevalence-of-hepatitis-c-virus-in-women-of-childbearing-age-in-2019-a-modeling-study/2024-11-13T00:04:53-07:00https://cdaf.org/conf-proceeding/catalytic-funding-for-viral-hepatitis-elimination-program-in-uzbekistan/2024-11-13T00:04:48-07:00https://cdaf.org/conf-proceeding/global-timing-of-hepatitis-c-virus-elimination-in-high-income-countries-an-updated-analysis/2024-11-13T00:04:43-07:00https://cdaf.org/conf-proceeding/anticipated-timing-of-elimination-of-hepatitis-c-virus-in-canadas-four-most-populous-provinces/2024-11-13T00:04:38-07:00https://cdaf.org/conf-proceeding/do-countries-have-the-right-policies-to-eliminate-viral-hepatitis-b-and-c-a-secondary-analysis-of-the-lancet-gastrohep-viral-hepatitis-commission/2024-11-13T00:04:05-07:00https://cdaf.org/conf-proceeding/the-hep-core-policy-score-a-european-hepatitis-c-national-policy-implementation-ranking/2024-11-13T00:03:58-07:00https://cdaf.org/conf-proceeding/eliminating-hepatitis-c-in-portugal-treatment-and-diagnosis-requirements-for-two-timelines/2024-11-13T00:06:15-07:00https://cdaf.org/conf-proceeding/global-timing-of-hepatitis-c-virus-elimination-estimating-the-year-countries-will-achieve-the-world-health-organization-elimination-targets/2024-11-13T00:05:19-07:00https://cdaf.org/conf-proceeding/achieving-accelerated-elimination-of-hepatitis-c-virus-infection-by-2025-a-case-study-in-france/2024-11-13T00:05:15-07:00https://cdaf.org/conf-proceeding/the-consensus-hepatitis-c-cascade-of-care-methodology-and-initial-findings-from-three-countries/2024-11-13T00:05:10-07:00https://cdaf.org/conf-proceeding/screening-strategies-for-hepatitis-c-virus-elimination-in-italy/2024-11-13T00:05:04-07:00https://cdaf.org/conf-proceeding/modeling-nafld-related-disease-progression-among-the-piter-svr12-cohort/2024-11-13T00:04:58-07:00https://cdaf.org/conf-proceeding/the-value-proposition-of-nash-therapy-on-the-burden-of-disease-related-to-obesity/2024-11-13T00:11:57-07:00https://cdaf.org/conf-proceeding/elimination-of-hepatitis-c-in-brazil-is-cost-saving/2024-11-13T00:11:47-07:00https://cdaf.org/conf-proceeding/should-changing-epidemiology-change-hav-vaccination-policy/2024-11-13T00:11:42-07:00https://cdaf.org/conf-proceeding/global-cascade-of-care-for-hbv-and-hcv/2024-11-13T00:11:37-07:00https://cdaf.org/conf-proceeding/estimates-and-projection-of-disease-burden-and-economic-analysis-for-hepatitis-b-in-viet-nam/2024-11-13T00:11:31-07:00https://cdaf.org/conf-proceeding/estimates-and-projection-of-disease-burden-and-economic-analysis-for-hepatitis-c-in-viet-nam/2024-11-13T00:11:25-07:00https://cdaf.org/conf-proceeding/achieving-world-health-organization-targets-for-hepatitis-b-by-2030-results-from-17-who-afro-countries/2024-11-13T00:11:04-07:00https://cdaf.org/conf-proceeding/achieving-world-health-organization-targets-for-hepatitis-b-in-infants-and-5-year-olds-by-2030-results-from-17-who-afro-countries/2024-11-13T00:10:59-07:00https://cdaf.org/conf-proceeding/forecasting-liver-disease-burden-based-on-a-real-life-cohort-of-linked-to-care-patients-in-italy-does-the-hidden-portion-of-the-iceberg-matter-to-reach-the-who-hcv-elimination-goals/2024-11-13T00:10:54-07:00https://cdaf.org/conf-proceeding/hepatitis-c-infection-in-the-pan-american-health-organization-region-the-current-burden-of-disease-and-a-road-map-for-achieving-the-world-health-organization-global-health-sector-strategy-goals/2024-11-13T00:10:48-07:00https://cdaf.org/conf-proceeding/impact-of-the-hepatitis-b-vaccine-birth-dose-on-perinatal-incidence-between-2017-2050-results-from-17-who-afro-countries/2024-11-13T00:10:43-07:00https://cdaf.org/conf-proceeding/micro-elimination-of-chronic-hepatitis-c-in-switzerland-modelling-the-swiss-hepatitis-strategy-goals-in-urban-and-rural-regions/2024-11-13T00:10:38-07:00https://cdaf.org/conf-proceeding/quantifying-the-impact-of-achieving-the-world-health-organization-global-health-sector-strategy-goals-for-hepatitis-c-in-the-afro-region/2024-11-13T00:10:30-07:00https://cdaf.org/conf-proceeding/quantifying-the-impact-of-achieving-the-world-health-organization-global-health-sector-strategy-goals-for-hepatitis-c-in-the-euro-region/2024-11-13T00:05:36-07:00https://cdaf.org/conf-proceeding/the-current-and-future-disease-burden-of-hepatitis-b-virus-in-the-general-population-and-among-five-year-olds-in-the-eastern-mediterranean-region/2024-11-13T00:05:31-07:00https://cdaf.org/conf-proceeding/the-global-prevalence-of-hbsag-by-age-in-2016-and-the-case-for-universal-treatment-in-low-and-middle-income-countries/2024-11-13T00:05:26-07:00https://cdaf.org/conf-proceeding/achieving-the-world-health-organization-global-health-sector-strategies-for-hepatitis-c-in-the-who-western-pacific-region-a-modelling-study/2024-11-13T00:08:51-07:00https://cdaf.org/conf-proceeding/disease-burden-of-hepatitis-b-in-the-kyrgyz-republic-a-focus-on-prevention/2024-11-13T00:08:44-07:00https://cdaf.org/conf-proceeding/eliminating-hepatitis-c-virus-hcv-in-indonesia/2024-11-13T00:08:34-07:00https://cdaf.org/conf-proceeding/hepatitis-c-infection-in-the-eastern-mediterranean-region-the-current-burden-of-disease-and-a-road-map-for-achieving-the-who-global-health-sector-strategy-targets/2024-11-13T00:08:23-07:00https://cdaf.org/conf-proceeding/quantifying-the-impact-of-achieving-the-world-health-organization-global-health-sector-strategy-targets-for-hepatitis-c-in-the-south-east-asia-region/2024-11-13T00:08:16-07:00https://cdaf.org/conf-proceeding/the-disease-burden-of-hepatitis-b-in-republic-of-uzbekistan-strategies-providing-hope-for-the-future/2024-11-13T00:08:08-07:00https://cdaf.org/conf-proceeding/the-disease-burden-of-hepatitis-b-and-c-from-20152030-the-long-and-winding-road-towards-elimination/2024-11-13T00:02:02-07:00https://cdaf.org/conf-proceeding/population-adjusted-prevalence-of-hepatitis-delta-virus-in-16-countries-and-territories/2024-11-13T00:02:40-07:00https://cdaf.org/conf-proceeding/the-elimination-of-hepatitis-c-in-the-cherokee-nation-the-impact-of-harm-reduction/2024-11-13T00:01:36-07:00https://cdaf.org/conf-proceeding/the-impact-of-vaccination-on-the-global-and-regional-paediatric-prevalence-of-hepatitis-b-from-1985-2022/2024-11-13T00:01:30-07:00https://cdaf.org/conf-proceeding/evaluation-of-global-progress-towards-hbv-and-hcv-elimination/2024-11-12T23:30:42-07:00https://cdaf.org/conf-proceeding/catalytic-funding-and-netflix-model-to-finance-viral-hepatitis-elimination/2024-11-13T00:01:56-07:00https://cdaf.org/conf-proceeding/hepatitis-c-prevalence-and-elimination-planning-in-pakistan-a-bottom-up-approach/2024-11-13T00:01:50-07:00https://cdaf.org/conf-proceeding/economic-investment-and-strategies-to-eliminate-chronic-hepatitis-c-in-mexico/2024-11-13T00:01:42-07:00https://cdaf.org/conf-proceeding/updated-evaluation-of-global-progress-towards-hbv-and-hcv-elimination-preliminary-data-through-2021/2024-11-13T00:02:32-07:00https://cdaf.org/conf-proceeding/the-incidence-of-chronic-hbv-by-age-2022/2024-11-13T00:02:25-07:00https://cdaf.org/conf-proceeding/re-engagement-as-an-hcv-elimination-strategy-a-scoping-review/2026-04-28T03:40:41-06:00https://cdaf.org/conf-proceeding/challenges-and-opportunities-for-reengaging-diagnosed-but-untreated-hbv-or-hcv-infected-individuals-in-the-us-to-care/2026-04-28T03:19:59-06:00https://cdaf.org/conf-proceeding/integrated-data-management-systems-accelerate-hcv-elimination-evidence-from-a-us-based-patient-re-engagement-program/2026-04-28T03:26:35-06:00https://cdaf.org/conf-proceeding/elimination-of-viral-hepatitis-worldwide/2026-04-28T03:29:51-06:00https://cdaf.org/conf-proceeding/global-analyses-on-diagnosis-treatment-gaps-and-elimination-progress-for-hcv/2026-04-28T03:31:20-06:00https://cdaf.org/conf-proceeding/the-future-of-hepatitis-c-elimination/2026-04-28T03:43:46-06:00https://cdaf.org/conf-proceeding/elimination-of-mother-to-child-transmission-in-low-income-countries-a-paradigm-shift-is-needed/2026-04-28T03:37:46-06:00https://cdaf.org/conf-proceeding/relinking-diagnosed-but-untreated-hbv-hcv-infected-individuals-to-care-in-the-united-states-interim-results/2026-04-28T03:39:38-06:00